VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Neptune Dash Technologies Corp. (TSX.V:DASH) (OTC:NPPTF) (FSE:1NW) (the "Company") announces it has closed a non-brokered private placement as part of a series of drawdowns on the Alumina Equity Agreement consisting of 1,250,000 units at a price of CAD$0.08 per unit for gross proceeds of $100,000.
Each unit consists of one common share and one transferable common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.13 for a period of three years from the issue date. The securities will be subject to a four month and one day hold period under securities laws.
The Company intends to use the proceeds from the private placement for strategic crypto currency acquisitions and associated administrative expenses.
About Neptune Dash Technologies Corp.
The Company primarily builds and operates Masternodes and invests in Node technologies. The Company also has a diversified cryptocurrency portfolio through investments made in Proof-Of-Stake tokens and their associated blockchain technologies.
XSOOH has always been at the forefront of hair care innovation, striving to deliver cutting-edge products that enhance the way customers achieve their desired looks. In a world where time is precious, XSOOH proudly announces the launch of the...
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
